416
Participants
Start Date
May 2, 2013
Primary Completion Date
March 9, 2016
Study Completion Date
March 9, 2016
Ciprofloxacin DPI (BAYQ3939)
Participants received 32.5 mg ciprofloxacin hydrated (corresponding to 50 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Placebo
Participants received placebo matched to ciprofloxacin 32.5 mg powder (containing 40 mg dry powder) administered BID (every 12 hours) using T-326 powder inhaler device.
Auckland
Vicente López
Auckland
Kogarah
Hellerup
Parkville
Tauranga
Box Hill
Prahran
Frankston
Talsu
Hamilton
Roskilde
Woolloongabba
Næstved
Cairns
Adelaide
Woodville
Adelaide
Toorak Gardens
Godoy Cruz
Krāslava
Wellington
Murdoch
Aarhus C
Christchurch
Cáceres
New York
Berlin
Berlin
New Hyde Park
Berlin
Santiago de Compostela
Philadelphia
Philadelphia
Varese
Geesthacht
Hamburg
Richmond
Abingdon
Pavia
Madrid
Madrid
Madrid
Pozuelo de Alarcón
Charleston
Lawrenceville
Marietta
Hanover
Hanover
Nîmes
Winter Park
Orlando
Oviedo
Miami
Weston
Montpellier
Trieste
Celebration
Jasper
Pontevedra
Verona
Hazard
Valencia
Valencia
Michigan City
Koblenz
Pisa
Frankfurt am Main
Chicago
Clermont-Ferrand
Chesterfield
Neu-Isenburg
Heidelberg
Bari
Fort Smith
McKinney
Fort Worth
Houston
Houston
Kingwood
Benevento
Toulon
Scottsdale
Flagstaff
Los Angeles
Ventura
Catania
Tacoma
Afula
Haifa
Haifa
Petah Tikva
Ramat Gan
Tel Aviv
Rehovot
Ashkelon
Beersheba
Jerusalem
Phoenix
Torrance
Dunedin
Farmington
Waterbury
Washington D.C.
Summit
Portland
Tyler
Spokane
Buenos Aires
Cottbus
Jena
Rome
Cagliari
Tōon
Nakagun
Kōshi
Matsusaka
Tsu
Sakai
Hamamatsu
Kiyose
Mitaka
Fukuoka
Daugavpils
Daugavpils
Jūrmala
Riga
Riga
Riga
Riga
Bratislava
Prešov
Elda
Badalona
L'Hospitalet de Llobregat
Sant Boi de Llobregat
Terrassa
Barcelona
Barcelona
Cambridge
Exeter
Plymouth
Torbay
Dundee
Belfast
Shrewsbury
Newcastle upon Tyne
London
Londonderry
Manchester